NASDAQ · CELUW

Celularity Inc.

$0.00 +$0.00 (+533.33%) 1D

Key Metrics

$41.59K
Market cap
P/E · TTM
$26.55M
Revenue · TTM
−$91.72M
Net income
EPS · TTM $-4.19
Dividend yield
Free cash flow −$13.42M
Beta · 1Y 3.29
EBITDA · TTM −$84.42M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    The stock moved +533.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 17
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    From its Jan 29 high, the share price fell 98%.

    Peak close $0.02 on Jan 29; trough close $0.00 on Jul 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -98%
  • Jul 9
    The stock moved +85.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$27.68M
Shares outstanding
52-wk range$0.00 – $0.06
Avg volume · 20D33.6K
Net cash −$27.64M
Book value / share$-1.74
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Celularity Inc.
IPO dateJul 19, 2021
Employees115

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.00
P/FCF
EV/EBITDA
EV/Sales1.04
Graham №

Profitability

Gross
Operating -345.4%
Net -345.4%
FCF -50.5%
ROE / ROIC 241.0% · 879.8%

Financial Health

Current ratio0.15
Quick ratio0.15
Debt / equity-0.89
Debt / EBITDA -0.40
Net cash −$27.64M
Working capital−$68.44M

Cash Flow · TTM

Operating CF −$13.25M
Capex −$161.00K
Free cash flow −$13.42M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-16.3
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings